Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2021 · 10-Q
Revenue$3.10M$3.10M+516.5% vs Q2 2020 Net Income-$39.07M-$39.07MN/M vs Q2 2020 EPS Diluted-$0.04-$0.04N/M vs Q2 2020 Operating Income-$39,312,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$33,231,000N/M Margins · derivedOperating margin-1270.2%+4756.3 pt vs Q2 2020
Net margin-1262.3%+4689.9 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end